Literature DB >> 22231235

SSc in 2011: From mechanisms to medicines.

Luc Mouthon1.   

Abstract

Findings from ongoing studies of imatinib in systemic sclerosis (SSc) were eagerly awaited in 2011, but results from these clinical trials have so far been disappointing. However, progress in the understanding of the mechanisms that underlie SSc pathogenesis could provide clues to novel targets for 2012 and beyond.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22231235     DOI： 10.1038/nrrheum.2011.203

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  10 in total

Review 1.  Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities.

Authors:  Swati Bhattacharyya; Jun Wei; John Varga
Journal:  Nat Rev Rheumatol       Date:  2011-10-25       Impact factor: 20.543

2.  Tissue factor-thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through up-regulation of endothelin receptor A.

Authors:  Akrivi Chrysanthopoulou; Ioannis Mitroulis; Konstantinos Kambas; Panagiotis Skendros; Ioannis Kourtzelis; Stergios Vradelis; George Kolios; Spyros Aslanidis; Michael Doumas; Konstantinos Ritis
Journal:  Arthritis Rheum       Date:  2011-11

Review 3.  Platelet contributions to the pathogenesis of systemic sclerosis.

Authors:  Arnold E Postlethwaite; Thomas M Chiang
Journal:  Curr Opin Rheumatol       Date:  2007-11       Impact factor: 5.006

4.  Imatinib as a novel therapeutic approach for fibrotic disorders.

Authors:  J H W Distler; O Distler
Journal:  Rheumatology (Oxford)       Date:  2008-11-23       Impact factor: 7.580

5.  Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.

Authors:  Jörg H W Distler; Astrid Jüngel; Lars C Huber; Ursula Schulze-Horsel; Jochen Zwerina; Renate E Gay; Beat A Michel; Thomas Hauser; Georg Schett; Steffen Gay; Oliver Distler
Journal:  Arthritis Rheum       Date:  2007-01

6.  Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.

Authors:  Janet Pope; Donna McBain; Lisa Petrlich; Sharon Watson; Louise Vanderhoek; Faye de Leon; Shannon Seney; Kelly Summers
Journal:  Arthritis Rheum       Date:  2011-11

7.  A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease.

Authors:  Dinesh Khanna; Rajeev Saggar; Maureen D Mayes; Fereidoun Abtin; Philip J Clements; Paul Maranian; Shervin Assassi; Rajan Saggar; Ram R Singh; Daniel E Furst
Journal:  Arthritis Rheum       Date:  2011-11

8.  Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice.

Authors:  Yoshinori Aono; Yasuhiko Nishioka; Mami Inayama; Momoyo Ugai; Jun Kishi; Hisanori Uehara; Keisuke Izumi; Saburo Sone
Journal:  Am J Respir Crit Care Med       Date:  2005-02-25       Impact factor: 21.405

9.  Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.

Authors:  Robert F Spiera; Jessica K Gordon; Jamie N Mersten; Cynthia M Magro; Mansi Mehta; Horatio F Wildman; Stacey Kloiber; Kyriakos A Kirou; Stephen Lyman; Mary K Crow
Journal:  Ann Rheum Dis       Date:  2011-03-11       Impact factor: 19.103

10.  Platelet-derived serotonin links vascular disease and tissue fibrosis.

Authors:  Clara Dees; Alfiya Akhmetshina; Pawel Zerr; Nicole Reich; Katrin Palumbo; Angelika Horn; Astrid Jüngel; Christian Beyer; Gerhard Krönke; Jochen Zwerina; Rudolf Reiter; Natalia Alenina; Luc Maroteaux; Steffen Gay; Georg Schett; Oliver Distler; Jörg H W Distler
Journal:  J Exp Med       Date:  2011-04-25       Impact factor: 14.307
  10 in total
  2 in total

1.  Systemic sclerosis immunoglobulin induces growth and a pro-fibrotic state in vascular smooth muscle cells through the epidermal growth factor receptor.

Authors:  Monique R Arts; Murray Baron; Nidaa Chokr; Marvin J Fritzler; Marc J Servant
Journal:  PLoS One       Date:  2014-06-13       Impact factor: 3.240

2.  B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis.

Authors:  Antoine François; Emmanuel Chatelus; Dominique Wachsmann; Jean Sibilia; Seiamak Bahram; Ghada Alsaleh; Jacques-Eric Gottenberg
Journal:  Arthritis Res Ther       Date:  2013-10-28       Impact factor: 5.156
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.